Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy

Tomokazu Kimura, Mizuki Onozawa, Jun Miyazaki, Taeko Matsuoka, Akira Joraku, Koji Kawai, Hiroyuki Nishiyama, Shiro Hinotsu, Hideyuki Akaza

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: To elucidate whether the disease characteristics and prognosis of stageIV prostate cancer treated with primary androgen deprivation therapy differ between young and elderly patients. Methods: A total of 3006 patients identified from the database of the Japan Study Group of Prostate Cancer were included in the analysis according to the following entry criteria: age of 75 years or less and stageIV disease. These patients were stratified into three groups: young (aged ≤55 years); middle-aged (aged ≧56 and ≤65 years); and elderly (aged ≧66 and ≤75 years). Their prognoses were analyzed both within age groups and according to whether or not there was metastasis. Results: The proportion of lymph node metastasis was significantly higher in the young group than in the elderly group (P=0.007), and there were no significant differences in other factors among age groups. The overall survival rate at 5 years in the young group was significantly worse than that in the middle-aged and elderly groups (26.6%, 59.7% and 55.3%, respectively) in patients with stageIV disease with metastasis, although there was no difference among age groups in patients with stageIV disease without metastasis. Multivariate analysis showed that younger age was an independent strong prognostic factor in stageIV disease with metastasis. Conclusions: Young men with metastatic prostate cancer have a poor prognosis. Young age is an independent prognostic factor in stageIV metastatic prostate cancer patients treated with primary androgen deprivation therapy.

Original languageEnglish
Pages (from-to)578-583
Number of pages6
JournalInternational Journal of Urology
Volume21
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Androgens
Prostatic Neoplasms
Neoplasm Metastasis
Age Groups
Therapeutics
Japan
Multivariate Analysis
Survival Rate
Lymph Nodes
Databases

Keywords

  • Primary androgen deprivation therapy
  • Prostate cancer
  • StageIV
  • Young men

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Kimura, T., Onozawa, M., Miyazaki, J., Matsuoka, T., Joraku, A., Kawai, K., ... Akaza, H. (2014). Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. International Journal of Urology, 21(6), 578-583. https://doi.org/10.1111/iju.12389

Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. / Kimura, Tomokazu; Onozawa, Mizuki; Miyazaki, Jun; Matsuoka, Taeko; Joraku, Akira; Kawai, Koji; Nishiyama, Hiroyuki; Hinotsu, Shiro; Akaza, Hideyuki.

In: International Journal of Urology, Vol. 21, No. 6, 2014, p. 578-583.

Research output: Contribution to journalArticle

Kimura, T, Onozawa, M, Miyazaki, J, Matsuoka, T, Joraku, A, Kawai, K, Nishiyama, H, Hinotsu, S & Akaza, H 2014, 'Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy', International Journal of Urology, vol. 21, no. 6, pp. 578-583. https://doi.org/10.1111/iju.12389
Kimura, Tomokazu ; Onozawa, Mizuki ; Miyazaki, Jun ; Matsuoka, Taeko ; Joraku, Akira ; Kawai, Koji ; Nishiyama, Hiroyuki ; Hinotsu, Shiro ; Akaza, Hideyuki. / Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. In: International Journal of Urology. 2014 ; Vol. 21, No. 6. pp. 578-583.
@article{9e2535d6aafe466fbf558ef7b1d5f4e6,
title = "Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy",
abstract = "Objectives: To elucidate whether the disease characteristics and prognosis of stageIV prostate cancer treated with primary androgen deprivation therapy differ between young and elderly patients. Methods: A total of 3006 patients identified from the database of the Japan Study Group of Prostate Cancer were included in the analysis according to the following entry criteria: age of 75 years or less and stageIV disease. These patients were stratified into three groups: young (aged ≤55 years); middle-aged (aged ≧56 and ≤65 years); and elderly (aged ≧66 and ≤75 years). Their prognoses were analyzed both within age groups and according to whether or not there was metastasis. Results: The proportion of lymph node metastasis was significantly higher in the young group than in the elderly group (P=0.007), and there were no significant differences in other factors among age groups. The overall survival rate at 5 years in the young group was significantly worse than that in the middle-aged and elderly groups (26.6{\%}, 59.7{\%} and 55.3{\%}, respectively) in patients with stageIV disease with metastasis, although there was no difference among age groups in patients with stageIV disease without metastasis. Multivariate analysis showed that younger age was an independent strong prognostic factor in stageIV disease with metastasis. Conclusions: Young men with metastatic prostate cancer have a poor prognosis. Young age is an independent prognostic factor in stageIV metastatic prostate cancer patients treated with primary androgen deprivation therapy.",
keywords = "Primary androgen deprivation therapy, Prostate cancer, StageIV, Young men",
author = "Tomokazu Kimura and Mizuki Onozawa and Jun Miyazaki and Taeko Matsuoka and Akira Joraku and Koji Kawai and Hiroyuki Nishiyama and Shiro Hinotsu and Hideyuki Akaza",
year = "2014",
doi = "10.1111/iju.12389",
language = "English",
volume = "21",
pages = "578--583",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy

AU - Kimura, Tomokazu

AU - Onozawa, Mizuki

AU - Miyazaki, Jun

AU - Matsuoka, Taeko

AU - Joraku, Akira

AU - Kawai, Koji

AU - Nishiyama, Hiroyuki

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

PY - 2014

Y1 - 2014

N2 - Objectives: To elucidate whether the disease characteristics and prognosis of stageIV prostate cancer treated with primary androgen deprivation therapy differ between young and elderly patients. Methods: A total of 3006 patients identified from the database of the Japan Study Group of Prostate Cancer were included in the analysis according to the following entry criteria: age of 75 years or less and stageIV disease. These patients were stratified into three groups: young (aged ≤55 years); middle-aged (aged ≧56 and ≤65 years); and elderly (aged ≧66 and ≤75 years). Their prognoses were analyzed both within age groups and according to whether or not there was metastasis. Results: The proportion of lymph node metastasis was significantly higher in the young group than in the elderly group (P=0.007), and there were no significant differences in other factors among age groups. The overall survival rate at 5 years in the young group was significantly worse than that in the middle-aged and elderly groups (26.6%, 59.7% and 55.3%, respectively) in patients with stageIV disease with metastasis, although there was no difference among age groups in patients with stageIV disease without metastasis. Multivariate analysis showed that younger age was an independent strong prognostic factor in stageIV disease with metastasis. Conclusions: Young men with metastatic prostate cancer have a poor prognosis. Young age is an independent prognostic factor in stageIV metastatic prostate cancer patients treated with primary androgen deprivation therapy.

AB - Objectives: To elucidate whether the disease characteristics and prognosis of stageIV prostate cancer treated with primary androgen deprivation therapy differ between young and elderly patients. Methods: A total of 3006 patients identified from the database of the Japan Study Group of Prostate Cancer were included in the analysis according to the following entry criteria: age of 75 years or less and stageIV disease. These patients were stratified into three groups: young (aged ≤55 years); middle-aged (aged ≧56 and ≤65 years); and elderly (aged ≧66 and ≤75 years). Their prognoses were analyzed both within age groups and according to whether or not there was metastasis. Results: The proportion of lymph node metastasis was significantly higher in the young group than in the elderly group (P=0.007), and there were no significant differences in other factors among age groups. The overall survival rate at 5 years in the young group was significantly worse than that in the middle-aged and elderly groups (26.6%, 59.7% and 55.3%, respectively) in patients with stageIV disease with metastasis, although there was no difference among age groups in patients with stageIV disease without metastasis. Multivariate analysis showed that younger age was an independent strong prognostic factor in stageIV disease with metastasis. Conclusions: Young men with metastatic prostate cancer have a poor prognosis. Young age is an independent prognostic factor in stageIV metastatic prostate cancer patients treated with primary androgen deprivation therapy.

KW - Primary androgen deprivation therapy

KW - Prostate cancer

KW - StageIV

KW - Young men

UR - http://www.scopus.com/inward/record.url?scp=84901691020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901691020&partnerID=8YFLogxK

U2 - 10.1111/iju.12389

DO - 10.1111/iju.12389

M3 - Article

C2 - 24405474

AN - SCOPUS:84901691020

VL - 21

SP - 578

EP - 583

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 6

ER -